A Study of the Effectiveness and Safety of Lanreotide Autogel/ Depot for Patients who have Lung Neuroendocrine Tumors

Overview

About this study

The purpose of this study is to evaluate the effectiveness and safety of lanreotide acetate analog/ depot plus the best standard care for the treatment of lung neuroendocrine tumors that have spread or can not be surgically removed.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Has metastatic and/or unresectable pathologically confirmed well-differentiated, typical or atypical neuroendocrine tumor of the lung
  • Histologic evidence of well differentiated neuroendocrine tumors (NETs) of the lung (typical and atypical according to the World Health Organisation (WHO criteria), evaluated locally)
  • Has a mitotic index < 2 mitoses/2 mm2 for typical carcinoid and < 10 mitoses/2 mm2 and/or foci of necrosis for atypical carcinoid
  • At least one measurable lesion of the disease on CT or MRI imaging RECIST 1.1
  • Positive Somatostatin receptors imaging

Exclusion Criteria

  • Poorly differentiated or high grade carcinoma, or neuroendocrine tumors not of lung origin
  • Has been treated with an Somatostatin analog at any time prior to randomization, except if that treatment was for less than 15 days (e.g. peri-operatively) of a short acting SSA or one dose of a long acting SSA and the treatment was received more than 6 weeks prior to randomization
  • Has been treated with Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization
  • Has been treated with more than one course of cytotoxic chemotherapy or molecular targeted therapy or interferon for Lung NET

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thorvardur Halfdanarson, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions